Literature DB >> 18405970

Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome.

Fernando Callera, Carlos O Lopes, Evandro S Rosa, Carla C Mulin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18405970     DOI： 10.1016/j.leukres.2008.02.004

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  10 in total

Review 1.  Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia.

Authors:  Benedito A Carneiro; Jason B Kaplan; Jessica K Altman; Francis J Giles; Leonidas C Platanias
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 2.  Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors.

Authors:  Daisuke Ikeda; SungGi Chi; Satoshi Uchiyama; Hirotaka Nakamura; Yong-Mei Guo; Nobuhiko Yamauchi; Junichiro Yuda; Yosuke Minami
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

Review 3.  Exploiting cellular pathways to develop new treatment strategies for AML.

Authors:  Amir T Fathi; Steven Grant; Judith E Karp
Journal:  Cancer Treat Rev       Date:  2010-01-06       Impact factor: 12.111

Review 4.  Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia.

Authors:  Ewa M Kosciuczuk; Diana Saleiro; Leonidas C Platanias
Journal:  Cytokine       Date:  2016-04-16       Impact factor: 3.861

Review 5.  The evolving landscape in the therapy of acute myeloid leukemia.

Authors:  Grace L Peloquin; Yi-Bin Chen; Amir T Fathi
Journal:  Protein Cell       Date:  2013-08-27       Impact factor: 14.870

Review 6.  New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.

Authors:  Amir T Fathi; Judith E Karp
Journal:  Curr Oncol Rep       Date:  2009-09       Impact factor: 5.075

7.  Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.

Authors:  Elspeth M Beauchamp; Sameem M Abedin; Sara G Radecki; Mariafausta Fischietti; Ahmet Dirim Arslan; Gavin T Blyth; Angela Yang; Connor Lantz; Alissa Nelson; Young Ah Goo; Imo Akpan; Elizabeth A Eklund; Olga Frankfurt; Eleanor N Fish; Paul M Thomas; Jessica K Altman; Leonidas C Platanias
Journal:  Blood       Date:  2018-12-26       Impact factor: 22.113

8.  Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation.

Authors:  Yan-Fang Tao; Zhi-Heng Li; Wei-Wei Du; Li-Xiao Xu; Jun-Li Ren; Xiao-Lu Li; Fang Fang; Yi Xie; Mei Li; Guang-Hui Qian; Yan-Hong Li; Yi-Ping Li; Gang Li; Yi Wu; Xing Feng; Jian Wang; Wei-Qi He; Shao-Yan Hu; Jun Lu; Jian Pan
Journal:  Oncol Rep       Date:  2017-02-02       Impact factor: 3.906

9.  Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance.

Authors:  Kristina B Emdal; Nicolàs Palacio-Escat; Caroline Wigerup; Akihiro Eguchi; Helén Nilsson; Dorte B Bekker-Jensen; Lars Rönnstrand; Julhash U Kazi; Alexandre Puissant; Raphaël Itzykson; Julio Saez-Rodriguez; Kristina Masson; Peter Blume-Jensen; Jesper V Olsen
Journal:  Cell Rep       Date:  2022-08-09       Impact factor: 9.995

10.  The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.

Authors:  Peter Tan; Ing Soo Tiong; Shaun Fleming; Giovanna Pomilio; Nik Cummings; Mark Droogleever; Julie McManus; Anthony Schwarer; John Catalano; Sushrut Patil; Sharon Avery; Andrew Spencer; Andrew Wei
Journal:  Oncotarget       Date:  2016-11-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.